A Comparative Study on the Safety and Efficacy of the Intra-Articular Injectable Filler ALLOHEAL in Patients With Knee Osteoarthritis
A legfontosabb adatok
- Ki végzi
- Endovision Co., Ltd.
- Hol
- Uijeongbu-si (Dél-Korea)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 286 fő, tervezett
- Kezdés
- 2025. febr. 4.
- Várható befejezés
- 2027. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- ALLOHEAL
- Conjuran
- A regiszteradat frissítve
- 2026. április 7.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with knee osteoarthritis and knee pain. It compares the knee injection ALLOHEAL with the injection Conjuran.
- Életkor
- 40 to under 80 years
- Nem
- Men and women
- A betegség stádiuma
- Knee osteoarthritis diagnosed by ACR guidelines within 24 weeks before screening or at screening. Kellgren-Lawrence grade I-III on X-ray. Knee pain for at least 8 weeks, with a weight-bearing pain score (VAS) of at least 40 mm. BMI less than 35 kg/m². Able to walk without a walker or cane, unless used for ≥24 weeks.
- Korábbi kezelés
- No surgery or arthroscopic treatment on the target knee within 24 weeks before screening.
A részvétel fő kizáró okai
- Needing surgery on the target knee, or loose knee ligaments of grade II or higher
- Fracture or knee deformity of ≥10°, or infection, inflammation, severe fluid or skin problems at the knee
- Rheumatoid arthritis, gout, fibromyalgia or other listed joint or connective tissue diseases
- Severe liver, heart or kidney disease, cancer within the past 5 years, or bleeding disorders such as hemophilia
- Allergy to pig-derived products or to parts of the study device
A regiszter feltételei, szó szerint
Mind a 6 feltétel megnézéseKevesebb
Ki vehet részt
- 1)Men and women aged ≥40 and <80 years at the date of signing the written informed consent; 2)Diagnosed with knee osteoarthritis according to the American College of Rheumatology (ACR) guidelines within 24 weeks prior to the screening visit or at the screening visit; 3)Experiencing pain in the osteoarthritic knee for at least 8 weeks. 4)At the screening visit, having a Kellgren-Lawrence grade I-III severity in the knee joint selected for evaluation based on X-ray findings (if both knees are symptomatic and show the same weight-bearing VAS score, the knee with the higher Kellgren-Lawrence grade will be selected as the target knee; the target knee cannot be changed during the clinical trial); 5)At the screening visit, having a weight-bearing VAS (Visual Analogue Scale) score of at least 40 mm in at least one knee joint (if both knees are symptomatic, the knee with the higher weight-bearing VAS score will be selected as the target knee; the target knee cannot be changed during the clinical trial); 6)At the screening visit, having a Body Mass Index (BMI) of less than 35 kg/m². 7)Able to walk without assistive devices such as a walker or cane (however, if the subject has been clinically using an assistive device for ≥24 weeks prior to the screening visit, assessment can be conducted including the device, and the same device must continue to be used until the completion of the trial); 8)Willing to voluntarily sign the written informed consent form. 9)Capable of understanding and complying with the procedures and visit schedule of the clinical trial
Ki nem vehet részt
- 1)History of surgical procedures (including meniscectomy or arthroscopic surgery) on the target knee within 24 weeks prior to the screening visit. (However, if the subject has a history of joint surgery on the contralateral knee, hip, or other joints that is unlikely to affect the clinical assessment of the target knee, participation in this clinical trial is allowed.) 2)History of arthroscopic treatment on the target knee within 24 weeks prior to the screening visit; 3)Requiring surgical intervention for the target knee at the screening visit. 4)Having ligament instability of grade II or higher in the target knee on physical examination at the screening visit (Grade 0: none, Grade I: 0-5 mm, Grade II: 5-10 mm, Grade III: >10 mm); 5)Presence of orthopedic conditions such as fractures or joint deformities in the target knee that may affect or interfere with treatment efficacy (joint deformity refers to varus or valgus deformity ≥10° in the knee joint); 6)Experiencing pain in the target knee due to surrounding joint structures or coexisting osteoarthritis in other areas (e.g., hip) that may influence assessment of knee pain; 7)Presence of the following comorbidities: Rheumatoid arthritis, spondyloarthritis, connective tissue disease, polymyalgia rheumatica, gout, Paget's disease, septic arthritis, psoriatic arthritis, joint fractures, osteonecrosis, fibromyalgia, chondrocalcinosis
- Severe hepatic, cardiac, or renal disease
- Malignant tumors within the past 5 years
- Coagulation disorders such as hemophilia 8) Infection or inflammation in the target knee joint. 9) Severe effusion in the target knee joint. 10) Local skin disorders at the target knee. 11)Hypersensitivity to porcine-derived products. 12)Hypersensitivity or history of adverse reactions to the main or other components of the investigational medical device used in this clinical trial
- Amyloidosis
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 40 és 80 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Dél-Korea.
- Seok Jung KimUijeongbu-si, Dél-KoreaContact: Seok jung kim, ProfessorRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
ENDOVISION Co., Ltd. has developed an intra-articular knee injection with sodium polynucleotide, chitosan, and type I collagen as its main components, and aims to demonstrate the non-inferiority of the investigational device, ALLOHEAL, compared with the control device, Conjuran®, when administered intra-articularly to patients with knee osteoarthritis for the purpose of reducing mechanical friction within the joint cavity.
A vizsgálat 2 csoportja
- ALLOHEAL GroupA vizsgált kezelés
Kezelés: ALLOHEAL
- Comparator GroupMár használt kezelés, összehasonlításként
Kezelés: Conjuran
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority, Pivotal Clinical Study to Evaluate the Safety and Efficacy of Intra-articular Filler 'ALLOHEAL' in Knee Osteoarthritis Patients
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07513415: ki vehet részt
- A regiszteradat frissítve
- 2026. április 7.